Arvinas, Inc (ARVN) is a publicly traded Healthcare sector company. As of July 28, 2026, ARVN trades at $8.23 with a market cap of $518.11M and a P/E ratio of -1.25. ARVN moved +2.49% today. Year to date, ARVN is -30.69%; over the trailing twelve months it is +4.85%. Its 52-week range spans $5.90 to $26.78. Analyst consensus is buy with an average price target of $15.10. Rallies surfaces ARVN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Arvinas Taps LITE, PPMI Programs to Advance ARV-102 PSP Trials in 2H 2026: Arvinas joined LITE and PPMI programs, leveraging shared preclinical and translational resources to advance ARV-102, its orally bioavailable, brain-penetrant PROTAC targeting LRRK2 in Parkinson’s disease and progressive supranuclear palsy. This collaboration will deepen understanding of LRRK2 biology and support Phase 1b and Phase 2 PSP trials scheduled 2H 2026.
| Metric | Value |
|---|---|
| Price | $8.23 |
| Market Cap | $518.11M |
| P/E Ratio | -1.25 |
| EPS | $-6.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.78 |
| 52-Week Low | $5.90 |
| Volume | 388.49K |
| Avg Volume | 0 |
| Revenue (TTM) | $78.50M |
| Net Income | $-367.30M |
| Gross Margin | 0.00% |
11 analysts cover ARVN: 0 strong buy, 6 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.10.